Full text is available at the source.
Abstract
Essence
The paper frames psychedelic drug discovery around assays for receptor agonism, behavior, and cellular plasticity.
Evidence
This preclinical review evaluates methods for psychedelics and non-hallucinogenic serotonin 2A receptor agonists, including biased signaling, automated behavioral phenotyping, neural remodeling, and activity-dependent gene expression.
Caveat
It offers a roadmap rather than therapeutic efficacy evidence, and human translation of receptor-selective psychedelic analogs remains unresolved.
Simplified
Psychedelic Science